Prot #MT-8421-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination with Nivolumab in Patients wit

Project: Research project

Project Details

StatusActive
Effective start/end date6/21/24 → 6/21/27

Funding

  • Molecular Templates, Inc. (Prot #MT-8421-001)